Cargando…

Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension

To explore the clinical features of coexisting primary aldosteronism (PA) and renal artery stenosis (RAS), we retrospectively analyzed records from 71 patients with PA with RAS and a control group of 121 patients with PA without RAS. Aldosterone-to-renin concentration ratio tests and computerized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lin, Xue, Jinhong, Zhou, Yi, Dong, Xueqi, Luo, Fang, Jiang, Xiongjing, Du, Xinping, Zhou, Xianliang, Meng, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927285/
https://www.ncbi.nlm.nih.gov/pubmed/35310978
http://dx.doi.org/10.3389/fcvm.2022.818872
_version_ 1784670413311180800
author Zhao, Lin
Xue, Jinhong
Zhou, Yi
Dong, Xueqi
Luo, Fang
Jiang, Xiongjing
Du, Xinping
Zhou, Xianliang
Meng, Xu
author_facet Zhao, Lin
Xue, Jinhong
Zhou, Yi
Dong, Xueqi
Luo, Fang
Jiang, Xiongjing
Du, Xinping
Zhou, Xianliang
Meng, Xu
author_sort Zhao, Lin
collection PubMed
description To explore the clinical features of coexisting primary aldosteronism (PA) and renal artery stenosis (RAS), we retrospectively analyzed records from 71 patients with PA with RAS and a control group of 121 patients with PA without RAS. Aldosterone-to-renin concentration ratio tests and computerized tomography (CT) scanning of the adrenal and renal arteries were routinely conducted to screen for PA and RAS. Color Doppler flow and/or magnetic resonance imaging were used as substitute testing of patients for whom CT was contraindicated. Standard percutaneous renal arteriography (PTRA) was considered for patients with RAS exceeding 70% based on non-invasive tests and for those without PTRA contraindications. The patients with PA with RAS were further divided into severe (RAS>70%) and moderate (50% < RAS <70%) RAS groups. The prevalence of RAS among PA patients was 6.9% (71/1,033), including 3.2% (33/1,033) with severe RAS. Compared with the PA without RAS group, the severe RAS group showed higher levels of systolic blood pressure (SBP) (171.82 ± 18.24 vs. 154.11 ± 18.96 mmHg; P < 0.001) and diastolic BP(DBP) (110.76 ± 15.90 vs. 91.73 ± 12.85 mmHg; P < 0.001) and prevalence of resistant hypertension (RH) (90.9 vs. 66.9%; P = 0.008), whereas the moderate RAS group merely showed higher DBP (98.63 ± 14.90 vs. 91.73 ± 12.85 mmHg; P = 0.006). The direct renin concentrations (DRCs) (5.37 ± 3.94 vs. 3.71 ± 2.10 μU/mL; P < 0.001) and false-negative rate (33.8 vs. 3.3%; P < 0.01) of PA screening tests were significantly higher in the PA with RAS group than in the control group, but only in severe RAS group, in subgroup analysis. Among patients who underwent successful treatment for severe RAS, mean DRC decreased from 11.22 ± 9.10 to 3.24 ± 2.69 μIU/mL (P < 0.001). Overall, the prevalence of RH decreased from 81.7 to 2.8% (P < 0.001) when both PA and RAS were treated with standard methods. PA with concurrent severe RAS is a condition that induces RH. PA can be easily missed in patients with coexisting RAS. RAS patients with RH after successful revascularization for RAS should be evaluated for coexisting PA.
format Online
Article
Text
id pubmed-8927285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89272852022-03-18 Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension Zhao, Lin Xue, Jinhong Zhou, Yi Dong, Xueqi Luo, Fang Jiang, Xiongjing Du, Xinping Zhou, Xianliang Meng, Xu Front Cardiovasc Med Cardiovascular Medicine To explore the clinical features of coexisting primary aldosteronism (PA) and renal artery stenosis (RAS), we retrospectively analyzed records from 71 patients with PA with RAS and a control group of 121 patients with PA without RAS. Aldosterone-to-renin concentration ratio tests and computerized tomography (CT) scanning of the adrenal and renal arteries were routinely conducted to screen for PA and RAS. Color Doppler flow and/or magnetic resonance imaging were used as substitute testing of patients for whom CT was contraindicated. Standard percutaneous renal arteriography (PTRA) was considered for patients with RAS exceeding 70% based on non-invasive tests and for those without PTRA contraindications. The patients with PA with RAS were further divided into severe (RAS>70%) and moderate (50% < RAS <70%) RAS groups. The prevalence of RAS among PA patients was 6.9% (71/1,033), including 3.2% (33/1,033) with severe RAS. Compared with the PA without RAS group, the severe RAS group showed higher levels of systolic blood pressure (SBP) (171.82 ± 18.24 vs. 154.11 ± 18.96 mmHg; P < 0.001) and diastolic BP(DBP) (110.76 ± 15.90 vs. 91.73 ± 12.85 mmHg; P < 0.001) and prevalence of resistant hypertension (RH) (90.9 vs. 66.9%; P = 0.008), whereas the moderate RAS group merely showed higher DBP (98.63 ± 14.90 vs. 91.73 ± 12.85 mmHg; P = 0.006). The direct renin concentrations (DRCs) (5.37 ± 3.94 vs. 3.71 ± 2.10 μU/mL; P < 0.001) and false-negative rate (33.8 vs. 3.3%; P < 0.01) of PA screening tests were significantly higher in the PA with RAS group than in the control group, but only in severe RAS group, in subgroup analysis. Among patients who underwent successful treatment for severe RAS, mean DRC decreased from 11.22 ± 9.10 to 3.24 ± 2.69 μIU/mL (P < 0.001). Overall, the prevalence of RH decreased from 81.7 to 2.8% (P < 0.001) when both PA and RAS were treated with standard methods. PA with concurrent severe RAS is a condition that induces RH. PA can be easily missed in patients with coexisting RAS. RAS patients with RH after successful revascularization for RAS should be evaluated for coexisting PA. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8927285/ /pubmed/35310978 http://dx.doi.org/10.3389/fcvm.2022.818872 Text en Copyright © 2022 Zhao, Xue, Zhou, Dong, Luo, Jiang, Du, Zhou and Meng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhao, Lin
Xue, Jinhong
Zhou, Yi
Dong, Xueqi
Luo, Fang
Jiang, Xiongjing
Du, Xinping
Zhou, Xianliang
Meng, Xu
Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title_full Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title_fullStr Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title_full_unstemmed Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title_short Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension
title_sort concurrent primary aldosteronism and renal artery stenosis: an overlooked condition inducing resistant hypertension
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927285/
https://www.ncbi.nlm.nih.gov/pubmed/35310978
http://dx.doi.org/10.3389/fcvm.2022.818872
work_keys_str_mv AT zhaolin concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT xuejinhong concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT zhouyi concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT dongxueqi concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT luofang concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT jiangxiongjing concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT duxinping concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT zhouxianliang concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension
AT mengxu concurrentprimaryaldosteronismandrenalarterystenosisanoverlookedconditioninducingresistanthypertension